Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients

NCT00410163 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukaemia, Lymphocytic, Chronic

Interventions

DRUG: Ofatumumab 500mg
DRUG: Ofatumumab 1000mg
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

GlaxoSmithKline